Decoy Therapeutics Files Prospectus Related To The Resale Of Up To 2,368,868 Common Shares
-SEC Filing
Stocks · News reference
Decoy Therapeutics To Exercise 1,184,434 Series B Warrants At $3.25/Share for ~$3.85M; Cuts Series A & C Warrant Prices To $3.25 And Issues 2,368,868 New Warrants At $3.25/Share
Decoy Therapeutics, Inc. (NASDAQ:DCOY) ("the Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Decoy Therapeutics Says Preclinical Data Show Single Intranasal Dose Of DCOY-CoV Maintains Drug Levels For Up To 7 Days; Expects Clinical Trials In 2027
8-K filing — Decoy Therapeutics Inc. (DCOY)
Filed: 2026-09-23 AccNo: 0001615219-26-000019 Size: 593 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Why Worthington Enterprises Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Worthington Enterprises surged 15.9% premarket after beating Q1 EPS and sales estimates; Wheeler REIT led gainers, while Jaguar Health and Biomea fell.